Medications
Medicines are used to both prevent and
treat
osteoporosis. Some medicines slow the rate of bone
loss or increase bone thickness. Even small amounts of new bone growth can
reduce your risk of broken bones.
If you take medicine for
osteoporosis, you will also need to take calcium and vitamin D supplements, eat
a healthy diet, and exercise regularly. A large part of treating or reducing
the effects of osteoporosis is
getting enough calcium and
vitamin D.
Medication Choices
Medicines for treatment and prevention
Medicines
used to prevent or treat osteoporosis include:
-
Bisphosphonates, such as alendronate (Fosamax),
ibandronate (Boniva), risedronate (Actonel), and zoledronic acid (Reclast),
which slow the rate of bone thinning and can lead to increased bone
density.4 These medicines may be used in men and
women.
Should I take bisphosphonate medicines for osteoporosis?
-
Raloxifene (Evista), a selective
estrogen receptor modulator (SERM), which is used only in women. Raloxifene
slows bone thinning and causes some increase in bone thickness.22
-
Calcitonin (Calcimar or Miacalcin), a
naturally occurring hormone that helps regulate calcium levels in your body and
is part of the bone-building process. When taken by shot or nasal spray, it
slows the rate of bone thinning. Calcitonin also relieves pain caused by
spinal compression fractures. Calcitonin is used in
men and women.
-
Parathyroid hormone (teriparatide
[Forteo]), used for the treatment of men and postmenopausal women with severe
osteoporosis who are at high risk for bone
fracture. It is given by injection.
Hormone therapy
Hormone therapy for osteoporosis
in women includes:
-
Estrogen. Estrogen without progestin
(estrogen replacement therapy, or ERT) may be used to treat osteoporosis in
women who have gone through
menopause and do not have a uterus. Because taking
estrogen alone increases the risk of developing cancer of the lining of the
uterus (endometrial cancer), ERT is only used if a woman has had her uterus
removed (hysterectomy).
-
Estrogen and progestin. In rare cases, the combination of estrogen and progestin
(hormone replacement therapy, or HRT) is recommended for women who have
osteoporosis.
For men,
testosterone (shots, gel, or patches) sometimes is
given to prevent osteoporosis caused by low testosterone levels, although use
of testosterone to treat osteoporosis has not been approved by the U.S. Food
and Drug Administration (FDA).
A woman's level of the hormone
estrogen, which affects the growth and loss of bone, decreases naturally during
and after menopause. Estrogen replacement therapy (ERT) or
combination estrogen/progesterone replacement therapy (HRT) can help
to reduce bone loss. Many experts recommend that long-term hormone replacement
therapy only be considered for women with a significant risk of osteoporosis
that outweighs the risks of taking HRT or ERT.
Researchers are
studying the effects of low-dose estrogen on women age 65 and older. An early,
small study indicates that a low estrogen dose (one-quarter that of
conventional ERT) may provide the same benefit (increased bone density and
decreased fractures) as the higher dose. In the same study, about one-third of
the women were given the low estrogen dose and progesterone (because these
women had not had hysterectomies). This group of women also experienced
increased bone density. But the long-term risks of taking low-dose estrogen
(and progesterone in one-third of the cases) were not studied and are
unclear.20 Experts recommend that HRT or ERT be used at
the lowest dose for the shortest length of time to reach your treatment goals.
While hormone therapy is typically not recommended for most women
with osteoporosis, if you are at high risk and cannot take other medicines,
your doctor may recommend it under certain circumstances. If you continue to
have bone loss while taking bisphosphonate medicine, such as risedronate
(Actonel) or alendronate (Fosamax), you may need to take both bisphosphonate
medicine and hormone therapy. Studies show that taking a bisphosphonate with
hormone therapy results in increased bone mass when compared to taking either
medicine alone.17, 18
What To Think About
Calcium, vitamin D,
bisphosphonates, calcitonin, and teriparatide may be used by men or women. HRT,
ERT, and raloxifene are prescribed only for women. Testosterone is prescribed
only for men.
Compression fractures
and other broken
bones resulting from osteoporosis can cause significant pain that lasts for
several months. Medicines available to relieve your pain include:
- Nonprescription
nonsteroidal anti-inflammatory drugs (NSAIDs), such as
ibuprofen and naproxen.
- Nonprescription
acetaminophen, such as Tylenol or Panadol.
- A
narcotic pain reliever, such as codeine or
morphine.
-
Calcitonin
, such as Calcimar or
Miacalcin.
If you are taking medicine but still have pain or have
side effects from the medicine, such as an upset stomach, talk with your
doctor.
Statins are medicines used to treat high
cholesterol, which increases the risk of developing
life-threatening diseases, such as
coronary artery disease, heart attack, and stroke.
Recent studies have reported conflicting results on statins' potential for
lowering a woman's risk of bone fractures. Evidence does not yet support the
use of statins to prevent or treat osteoporosis.23, 24
Anderson JJB (2008). Nutrition and bone health. In LK
Mahan, S Escott-Stump, eds., Krause's Food and Nutrition Therapy, pp. 614–635. St. Louis: Saunders Elsevier.
Feldstein A, et al. (2003). Bone mineral density
measurement and treatment for osteoporosis in older individuals with fractures.
Archives of Internal Medicine, 163(18):
2165–2172.
Cummings SR (2002). Bone biology, epidemiology, and
general principles. In SR Cummings et al., eds., Osteoporosis: An Evidence-Based Guide to Prevention and Management, pp. 3-25.
Philadelphia: American College of Physicians–American Society of Internal
Medicine.
American College of Obstetricians and Gynecologists
(2004, reaffirmed 2008). Clinical management guidelines for
obstetrician-gynecologists. Osteoporosis. ACOG Practice Bulletin No. 50.
Obstetrics and Gynecology, 103(1): 203–216.
Nieves J (2002). Nutrition. In SR Cummings et al.,
eds., Osteoporosis: An Evidence-Based Guide to Prevention and Management, pp. 85–108. Philadelphia: American College of
Physicians–American Society of Internal Medicine.
Tucker KL, et al. (2006). Colas, but not other carbonated beverages, are associated with low bone mineral density in older women: The Framingham osteoporosis study. American Journal of Clinical Nutrition, 84(4): 936–942.
U.S. Preventive Services Task Force (2002). Screening
for osteoporosis in postmenopausal women: Recommendations and rationale.
Annals of Internal Medicine, 137(6):
526–528.
Qaseem A, et al. (2008). Screening for osteoporosis in
men: A clinical practice guideline from the American College of Physicians.
Annals of Internal Medicine, 148(9):
680–684.
Bischoff-Ferrari HA, et al. (2004). Effect of vitamin
D on falls: A meta-analysis. JAMA, 291(16):
1999–2006.
Mosekilde L, et al. (2008). Fracture prevention in
postmenopausal women, search date January 2007. Online version of
BMJ Clinical Evidence. Also available online:
http://www.clinicalevidence.com.
Jackson RD, et al. (2006). Calcium plus vitamin D supplementation and the risk of fractures. New England Journal of Medicine, 354(7): 669–683.
Bonaiuti D, et al. (2006). Exercise for preventing and
treating osteoporosis in postmenopausal women. Cochrane Database of Systematic Reviews (1). Oxford: Update Software.
National Osteoporosis Foundation (2008).
Prevention. Available online:
www.nof.org/prevention/index.htm.
Cummings SR, Melton LJ III (2002). Epidemiology and
outcomes of osteoporotic fractures. Lancet, 359(9319):
1761–1767.
Silverman SL (2002). Calcitonin. In SR Cummings et
al., eds., Osteoporosis: An Evidence-Based Guide to Prevention and Management, pp. 197–208. Philadelphia: American College of
Physicians–American Society of Internal Medicine.
Cosman F (2002). Selective estrogen-receptor
modulators. In SR Cummings et al., eds., Osteoporosis: An Evidence-Based Guide to Prevention and Management, pp. 151–167.
Philadelphia: American College of Physicians–American Society of Internal
Medicine.
Harris ST, et al. (2001). Effect of combined
risedronate and hormone replacement therapies on bone mineral density in
postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 86(5): 1890–1897.
Greenspan SL, et al. (2003). Combination therapy with
hormone replacement and alendronate for prevention of bone loss in elderly
women. JAMA, 289(19): 2525–2533.
U.S. Food and Drug Administration (2002). FDA approves
teriparatide to treat osteoporosis. FDA Talk Paper T02-49. Available online:
http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01176.html.
Prestwood KM, et al. (2003). Ultralow-dose micronized
17 B-estradiol and bone density and bone metabolism in older women.
JAMA, 290(8): 1042–1048.
Fiechtner JJ (2003). Hip fracture prevention.
Postgraduate Medicine, 114(3): 22–32.
Drugs for postmenopausal osteoporosis (2008).
Treatment Guidelines From The Medical Letter, 6(74):
67–74.
LaCroix AZ, et al. (2003). Statin use, clinical
fracture, and bone density in postmenopausal women: Results from the Women's
Health Initiative Observational Study. Annals of Internal Medicine, 139(2): 97–104.
Bauer DC, et al. (2004). Use of statins and fracture:
Results of 4 prospective studies and cumulative meta-analysis of observational
studies and controlled trials. Archives of Internal Medicine, 164(2): 146–152.
Parker MJ, et al. (2006). Effectiveness of hip
protectors for preventing hip fractures in elderly people: Systematic review.
BMJ, 332(7541): 571–574.
Zhang X, et al. (2005). Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. Archives of Internal Medicine, 165(16): 1890–1895.